Narjust Florez, Associate Director of Cancer Care Equity Program, Thoracic Medical Oncologist
Dr. Narjust Florez is originally from Venezuela. She completed her internal medicine residency at Rutgers New Jersey Medical School and fellowship at the Mayo Clinic in Rochester, Minnesota, where she was the chief fellow from 2018 -2019.
She is the Associate Director of the Cancer Care Equity Program, a thoracic medical oncologist at the Dana-Farber Cancer Institute/Harvard Cancer Center and a Assistant Professor of Medicine at Harvard Medical School. In 2022, Dr. Florez also became the first Latina to hold an Associate Editor position in oncology as the new Associate Editor for Diversity, Equity and Inclusion at the JAMA Oncology Journal.
Dr. Florez’s clinical interests include targeted therapy for lung cancer and the care of women with lung cancer, including their unique aspects of cancer survivorship. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstrazenecaTopic:targereted therapyDate added:11/16/2022Date updated:11/16/2022Relationship end date:11/20/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PfizerTopic:Advisory boardDate added:11/16/2022Date updated:11/16/2022Relationship end date:11/26/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BMSTopic:Advisory boardDate added:11/16/2022Date updated:11/16/2022Relationship end date:11/19/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:DSITopic:Advisory boardDate added:11/16/2022Date updated:11/16/2022Relationship end date:11/19/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:NeogenomicsTopic:Advisory boardDate added:11/16/2022Date updated:11/16/2022Relationship end date:11/26/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:MerckTopic:advisory boardDate added:11/16/2022Date updated:11/16/2022Relationship end date:11/26/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BMSTopic:CME contentDate added:11/16/2022Date updated:11/16/2022Relationship end date:11/13/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:JanssenTopic:CME contentDate added:11/16/2022Date updated:11/16/2022Relationship end date:11/17/2025